相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Modulation of bile acid profile by gut microbiota in chronic hepatitis B
Xiaolin Wang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
Makoto Chuma et al.
CANCERS (2020)
Establishment of a Patient-Derived Xenograft Tumor From Hepatitis C-Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy
Mustafa Nazzal et al.
HEPATOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades
Taisuke Hoshi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction
Fasiha Kanwal et al.
GASTROENTEROLOGY (2019)
Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met
Shuwei Chen et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
α2,6-Sialylation promotes immune escape in hepatocarcinoma cells by regulating T cell functions and CD147/MMP signaling
Liping Wang et al.
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2019)
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update
Norihiro Kokudo et al.
HEPATOLOGY RESEARCH (2019)
Engineering a humanized telomerase reverse transcriptase gene in mouse embryonic stem cells
De Cheng et al.
SCIENTIFIC REPORTS (2019)
RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma
Shaw M. Akula et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Role of the transcriptional coactivators YAP/TAZ in liver cancer
Shihao Zhang et al.
CURRENT OPINION IN CELL BIOLOGY (2019)
Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway
Qing-Feng Xiang et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2019)
ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage
Asmi Chakraborty et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis
Thoetchai (Bee) Peeraphatdit et al.
JOURNAL OF HEPATOLOGY (2018)
miR-9 inhibits the metastatic ability of hepatocellular carcinoma via targeting beta galactoside alpha-2,6-sialyltransferase 1
Yi Han et al.
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
Masahiro Matsuki et al.
CANCER MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis
Takahiro Kodama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis
Katharina Brandl et al.
JOURNAL OF HEPATOLOGY (2018)
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
Lixia Gao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15
Mei Zhou et al.
JOURNAL OF HEPATOLOGY (2017)
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Adrian Ally et al.
CELL (2017)
Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
Zeynep Firtina Karagonlar et al.
CANCER SCIENCE (2016)
Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro
Zhen Qu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Recurrence of Hepatocellular Cancer After Resection Patterns, Treatments, and Prognosis
Parissa Tabrizian et al.
ANNALS OF SURGERY (2015)
Fibroblast Growth Factor Signaling in the Vasculature
Xuehui Yang et al.
CURRENT ATHEROSCLEROSIS REPORTS (2015)
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
Kornelius Schulze et al.
NATURE GENETICS (2015)
Fibroblast Growth Factor Signaling in Liver Carcinogenesis
Dalbir S. Sandhu et al.
HEPATOLOGY (2014)
Expression of Fibroblast Growth Factor 19 Is Associated with Recurrence and Poor Prognosis of Hepatocellular Carcinoma
Jiyeon Hyeon et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
Endocrine fibroblast growth factors 15/19 and 21: from feast to famine
Matthew J. Potthoff et al.
GENES & DEVELOPMENT (2012)
Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
Dorothy M. French et al.
PLOS ONE (2012)
Hepatocellular carcinoma in developing countries: Prevention, diagnosis and treatment
Michael C. Kew
WORLD JOURNAL OF HEPATOLOGY (2012)
Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening
Eric T. Sawey et al.
CANCER CELL (2011)
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Carol Kilkenny et al.
PLOS BIOLOGY (2010)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection
Jason B. Bell et al.
NATURE PROTOCOLS (2007)
Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy
W Sieghart et al.
JOURNAL OF HEPATOLOGY (2006)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
A mouse model of hepatocellular carcinoma - Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice
K Nicholes et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
分享论文
